MEDITOPE BIOSCIENCES ANNOUNCES ISSUANCE OF ADDITIONAL PATENT FOR SNAP TECHNOLOGY
Pasadena, Calif., February 25, 2015 -- Meditope Biosciences, Inc., a biotechnology company developing novel antibody-based products using its proprietary technology platform, today announced the issuance of a new patent, U.S. Patent No. 8,962,804. The patent, entitled "Meditopes and Meditope-Binding Antibodies and Uses Thereof," is the second issued patent relating to the company's Site-specific novel Antibody Platform (SnAP).
"We are delighted about issuance of this second patent related to development of novel antibody-based products with our proprietary SnAP technology," said Stephanie Hsieh, Meditope's president and chief executive officer. "We continue to make great progress at identifying potential antibody drug-conjugate product candidates that leverage our technology, while we explore its many applications through strategic partnering opportunities."
About Meditope Biosciences, Inc.
Meditope Biosciences is a biotechnology company developing novel antibody-based cancer products using its SnAP technology (Site-specific novel Antibody Platform). Discovered at City of Hope, a National Cancer Institute designated Comprehensive Cancer Center, SnAP is capable of turning any antibody into a proprietary, site-specific "Lego-like" system that is able to attach and detach nearly anything to an antibody without the need for chemical conjugation. Meditope's SnAP technology has the potential to advance the antibody market by enabling production of an array of new therapeutic and diagnostic products. More information can be found by visiting www.meditope.com.